Current FDA-approved agents for unresectable metastatic melanoma include chemotherapy, BRAF inhibitors, MEK inhibitors, ipilimumab, a CTLA-4 inhibitor, and anti-PD1 antibodies pembolizumab and nivolumab. The gene discussed is PDCD1; the disease is metastatic melanoma.